Pulling SEC filings + quote and writing the call…
Pulling SEC filings + quote and writing the call…
SANGAMO THERAPEUTICS, INC
Next earnings ≈ Aug 13, 2026 · est. from filing cadence
Last earnings +0.0% on 2026-05-14
High return on equity (861.6%); but revenue fell -31.6% YoY.
Rules-based read computed from SEC figures — no Anthropic key set. Add ANTHROPIC_API_KEY to .env.local for a full Claude analysis.
SANGAMO THERAPEUTICS, INC shows $39.6M in FY2025 revenue (-31.6% YoY), a -310.8% net margin, and 861.6% ROE.
The risks, catalysts, 12-month price target and the cited SEC figures behind this rating — with Pro.
Unlock with Pro€15/mo · cancel anytime
Sources: SEC EDGAR (CIK 0001001233, latest 10-Q filed 2026-05-14) · EODHD · rules-based read · as of 6/18/2026, 12:46:37 PM.
Research and education only — not financial advice. Calls are generated from SEC filings and a delayed/third-party price feed, may be wrong or out of date, and are not a recommendation to buy or sell any security. Do your own research.
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | $111M | $111M | $176M | $57.8M | $39.6M |
| Gross profit | — | — | — | — | — |
| Operating income | -$183M | -$201M | -$274M | -$104M | -$121M |
| Net income | -$178M | -$192M | -$258M | -$97.9M | -$123M |
| Diluted EPS | -$1.23 | -$1.25 | -$1.48 | -$0.49 | -$0.44 |
| Net margin | -161.1% | -172.8% | -146.3% | -169.4% | -310.8% |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
501 tracked peers · median
Last 90 days: 0 open-market buys · 2 sales
| 2026-05-25 | Davis Gregory D Head of Research & Technology | Tax | 1.63K @ $0.17 | $284.11 |
| 2026-05-25 | Jain Nikunj Principal Accounting Officer | Tax | 1.92K @ $0.17 | $334.48 |
| 2026-05-25 | Dubois-Stringfellow Nathalie SVP-CHIEF DEVELOPMENT OFFICER | Tax | 4.04K @ $0.17 | $703.47 |
| 2026-05-25 | Willoughby Scott B. SVP, CHIEF LEGAL OFFICER, SECY | Tax | 4.04K @ $0.17 | $703.47 |
| 2026-05-25 | Macrae Sandy PRESIDENT, CEO AND DIRECTOR | Tax | 12.6K @ $0.17 | $2.20K |
| 2026-04-22 | Davis Gregory D Head of Research & Technology | Sell | 69.8K @ $0.25 | $17.7K |
| 2026-04-21 | Dubois-Stringfellow Nathalie SVP-CHIEF DEVELOPMENT OFFICER | Sell | 346K @ $0.26 | $89.2K |